PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-12.41%
Revenue decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
Gross profit decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
29.66%
Similar R&D growth to AVXL's 33.38%. Walter Schloss would investigate industry innovation requirements.
16.61%
G&A growth above 1.5x AVXL's 8.97%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.48%
Similar operating expenses growth to AVXL's 26.96%. Walter Schloss would investigate norms.
25.48%
Similar total costs growth to AVXL's 26.96%. Walter Schloss would investigate norms.
No Data
No Data available this quarter, please select a different quarter.
3.10%
D&A growth less than half of AVXL's 25.54%. David Dodd would verify if efficiency is sustainable.
-28.10%
EBITDA decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-46.25%
EBITDA margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-27.47%
Both companies show declining income. Martin Whitman would check industry conditions.
-45.52%
Operating margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-14.81%
Other expenses reduction while AVXL shows 52.18% growth. Joel Greenblatt would examine advantage.
-27.92%
Both companies show declining income. Martin Whitman would check industry conditions.
-46.04%
Pre-tax margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-27.92%
Both companies show declining income. Martin Whitman would check industry conditions.
-46.04%
Net margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-20.00%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-20.00%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
6.47%
Share count reduction below 50% of AVXL's 2.91%. Michael Burry would check for concerns.
6.47%
Diluted share reduction below 50% of AVXL's 2.91%. Michael Burry would check for concerns.